Identification of false-positive CBFbeta/MYH11 RT-PCR results

Area of Science:

• Molecular Biology
• Oncology
• Genetics

Background:

• Acute myeloid leukemia (AML) is often associated with specific genetic abnormalities.
• The inv(16)(p13q22) translocation, leading to CBFbeta/MYH11 fusion transcripts, is a key diagnostic marker in AML.
• Accurate detection of these transcripts is crucial for diagnosis and treatment decisions.

Purpose of the Study:

• To investigate the cause of persistent false positive results in RT-PCR detection of CBFbeta/MYH11 transcripts.
• To identify the source of non-specific amplification in RT-PCR assays for AML diagnosis.

Main Methods:

• Reverse Transcription Polymerase Chain Reaction (RT-PCR) was used to detect CBFbeta/MYH11 transcripts.
• Analysis of amplified sequences to identify the origin of false positive signals.
• Primer sequence analysis for homology with known genomic or transcript sequences.

Main Results:

• Persistent false positive results were observed with a published RT-PCR method.
• The false positives were attributed to the amplification of an intronic MYH11 sequence.
• This non-specific amplification resulted from partial homology between the CBFbeta3 primer and the intronic MYH11 sequence.
• Contaminating DNA or unspliced RNA transcripts likely served as templates for this aberrant amplification.

Conclusions:

• The published RT-PCR method for detecting CBFbeta/MYH11 transcripts in AML is unreliable due to non-specific amplification.
• Primer design and potential for amplifying intronic sequences must be carefully considered in diagnostic assay development.
• Optimization of RT-PCR protocols is necessary to ensure accurate detection of fusion transcripts and reliable diagnosis of AML.